| Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. | |
| | |
MedLine Citation:
|
PMID: 10565755 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To compare positron emission tomography (PET) using 18-fluoro-2-deoxyglucose (FDG) with conventional clinical staging in unselected patients with germ cell cancer. METHODS: Fifty patients underwent PET scans of the abdomen (n = 50) and chest (n = 41 ) after the initial diagnosis. PET images were evaluated qualitatively and quantitatively using standardized uptake values (SUVs). The results were compared with computed tomography (CT) results and tumor markers (human chorionic gonadotropin, alpha-fetoprotein, and lactate dehydrogenase). Retroperitoneal lymphadenectomy in 12 patients and clinical staging, including follow-up data in all patients, were taken as a reference standard. RESULTS: PET detected metastases in 13 (87%) of 15 patients and excluded metastases in 33 (94%) of 35 patients. A sensitivity of 73% and a specificity of 94% were obtained using CT. The respective values for tumor marker determination were 67% and 100%. Retroperitoneal metastases were detected in 2 patients by PET only and in 1 patient by CT only. In the latter patient, surgery of a residual mass after chemotherapy revealed a well-differentiated teratoma. False-negative findings with PET and CT occurred in 2 patients with retroperitoneal metastases approximately 10 mm in size. False-positive findings were due to sarcoidosis or to muscular activity of the neck. Quantitative FDG uptake was very heterogeneous, with an SUV ranging from 1.8 to 17.3. CONCLUSIONS: FDG PET has the potential to improve clinical staging of testicular cancer. However, PET, as well as CT, is limited in the detection of small retroperitoneal lymph node metastases. |
| | |
Authors:
|
U Cremerius; J E Wildberger; H Borchers; M Zimny; G Jakse; R W Günther; U Buell |
Related Documents
:
|
17015895 - Yield of brain 18f-fdg pet in evaluating patients with potentially operable non-small c... 16883005 - Increased 18f-fdg uptake in degenerative disease of the spine: characterization with 18... 18651155 - Tumour length measured on pet-ct predicts the most appropriate stage-dependent therapeu... 12815135 - Staging of non-small-cell lung cancer with integrated positron-emission tomography and ... 19884165 - Variability of ascending aorta diameter measurements as assessed with electrocardiograp... 12924505 - Hypersomnia and low csf hypocretin-1 (orexin-a) concentration in a patient with multipl... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article |
Journal Detail:
|
Title: Urology Volume: 54 ISSN: 1527-9995 ISO Abbreviation: Urology Publication Date: 1999 Nov |
Date Detail:
|
Created Date: 1999-12-21 Completed Date: 1999-12-21 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0366151 Medline TA: Urology Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 900-4 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine, Aachen University of Technology, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Fluorodeoxyglucose F18 / diagnostic use* Humans Male Middle Aged Neoplasm Staging Neoplasms, Germ Cell and Embryonal / pathology*, radionuclide imaging*, secondary Predictive Value of Tests Radiopharmaceuticals / diagnostic use* Testicular Neoplasms / pathology*, radionuclide imaging* Tomography, Emission-Computed* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sperm cryopreservation in patients with testicular cancer.
Next Document: Relationship among pediatric voiding dysfunction and vesicoureteral reflux and renal scars.